Site icon pharmaceutical daily

Shionogi to Present New Data at IDWeek 2019

BusinessWire

– Including Cefiderocol Phase III APEKS-NP Trial as Late-breaker Oral Presentation –

OSAKA, Japan & FLORHAM PARK, N.J.–(BUSINESS WIRE)–Shionogi & Co., Ltd. (hereafter “Shionogi”) today announced that the company will deliver 20 data presentations for Shionogi compounds, including a late-breaker oral presentation of cefiderocol Phase III APEKS-NP trial results, at IDWeek™, October 2-6, 2019, in Washington, D.C.

Cefiderocol is a siderophore cephalosporin with a novel mechanism for penetrating the outer cell membrane of Gram-negative pathogens including multidrug-resistant strains. At IDWeek, Shionogi will share findings from the APEKS-NP trial evaluating the investigational antibiotic cefiderocol in adults with hospital-acquired bacterial pneumonia, ventilator-associated bacterial pneumonia, or healthcare-associated bacterial pneumonia caused by Gram-negative pathogens. Additionally, Shionogi will share findings from other studies investigating cefiderocol, and the prevalence and characterization of carbapenem-resistant bacterial infections.

The company will also present data for XOFLUZA™ (baloxavir marboxil), a first-in-class, one-dose oral medicine for the treatment of acute uncomplicated influenza in patients 12 years of age and older who have been symptomatic for no more than 48 hours.

“This is the first release of data from the Phase III APEKS-NP trial. The results strengthen our belief that cefiderocol has the potential to make a meaningful difference for patients fighting life-threatening Gram-negative infections,” said Dr. Tsutae “Den” Nagata, Chief Medical Officer, Shionogi.

Presentations will include data from company-sponsored or investigator-initiated investigational studies. The details for the presentations are as follows:

Oral presentation about cefiderocol

Oral presentation #LB4: Efficacy and Safety of Cefiderocol versus High-Dose Meropenem in Patients with Nosocomial Pneumonia – Results of a Phase 3 Randomized, Multicenter, Double-Blind, Non-Inferiority Study

Date and time: October 3, 2:15-2:25 p.m.

Session title and location: Late Breaker Oral Abstract Session 1; Room 209 ABC of the Walter E. Washington Convention Center

All poster presentations will take place on the following dates and times; session titles and location:

Cefiderocol

Date and time: October 3, 12:15 p.m.-1:30 p.m.

Location: Poster Hall at the Walter E. Washington Convention Center

Session title: Bacteremia, CLABSI, and Endovascular Infections

Session title: HAI: MDRO – GNR Epidemiology, CRE

Session title: HAI: MDRO – GNR Epidemiology, Acinetobacter

Session title: Novel Antimicrobials and Approaches Against Resistant Bugs

Date and time: October 4, 12:15 p.m.-1:30 p.m.

Location: Poster Hall at the Walter E. Washington Convention Center

Session title: Urinary Tract Infections

Session title: PK/PD & Susceptibility Testing

Date and time: October 5, 12:15 p.m.-1:30 p.m.

Location: Poster Hall at the Walter E. Washington Convention Center

Session title: Clinical Outcomes of Infections with Resistant Organisms

XOFLUZA

Date and time: October 4, 12:15 p.m.-1:30 p.m.

Location: Poster Hall at the Walter E. Washington Convention Center

Session title: PK/PD & Susceptibility Testing

About Cefiderocol–An Investigational Antibiotic Agent

Cefiderocol is a parenteral siderophore cephalosporin with a novel mechanism for penetrating the outer cell membrane of Gram-negative pathogens including multidrug-resistant strains. Cefiderocol binds to ferric iron and is actively transported into bacterial cells through the outer membrane via the bacterial iron transporters, which function to incorporate this essential nutrient for bacteria.1 In addition, cefiderocol can also enter cells by passive diffusion through porin channels and is stable against all known classes of beta-lactamases, including both the metallo- and serine-beta-lactamases.2 These mechanisms allow cefiderocol to achieve higher concentrations in the periplasmic space where it can bind to receptors and inhibit cell wall synthesis in the bacterial cells.3 Data from multinational surveillance studies for cefiderocol demonstrated potent in vitro activity against a wide spectrum of Gram-negative pathogens including carbapenem-resistant Acinetobacter baumannii (A. baumannii), Pseudomonas aeruginosa (P. aeruginosa), Enterobacteriaceae, and Stenotrophomonas maltophilia (S. maltophilia).4 Cefiderocol has poor in vitro activity against Gram-positive or anaerobic bacteria. The clinical significance of in vitro data is unknown.

Shionogi submitted a New Drug Application to the U.S. Food and Drug Administration (FDA). Cefiderocol was designated as a Qualified Infectious Disease Product (QIDP) by the FDA with the assigned action date of November 14, 2019 under the Prescription Drug User-Fee Act (PDUFA). Additionally, Shionogi also submitted a marketing authorization application of cefiderocol to the European Medicines Agency and it was accepted in March 2019.5

About Gram-negative Infections

The increasing resistance of many infections caused by Gram-negative bacteria to existing therapies, including carbapenem-resistant Enterobacteriaceae and non-fermenting species such as P. aeruginosa, A. baumannii, and S. maltophilia, means there is a critical need for new, effective therapies.4, 6-9 There are an increasing number of Gram-negative pathogens resistant to multiple antibiotics, making them difficult to treat and resulting in high mortality rates.10 In the U.S., at least two million people are infected with antibiotic-resistant bacteria, and at least 23,000 people die as a result each year.11 In the EU, about 25,000 patients die from an infection with the selected multidrug-resistant bacteria.12 The World Health Organization and the Centers for Disease Control and Prevention have identified carbapenem-resistant strains of Enterobacteriaceae, P. aeruginosa, and A.baumannii as the top priority in the research and development of new antibiotics.6,11

About XOFLUZA™ (baloxavir marboxil)

XOFLUZA, discovered by Shionogi, has a novel mechanism of action that inhibits cap-dependent endonuclease in the polymerase acidic (PA) protein (in the United States Prescribing Information, this enzyme is stated as polymerase acidic endonuclease), an enzyme essential for viral replication. The regimen for XOFLUZA is one-oral dose to treat uncomplicated influenza, which is different from all currently available antiviral treatments. In non-clinical studies, XOFLUZA demonstrated an antiviral effect against a wide range of influenza viruses including oseltamivir-resistant strains and avian strains (H7N9, H5N1).13-14 XOFLUZA was approved and is now available in Japan for the treatment of influenza Types A and B in adults and paediatric patients.15 In addition, XOFLUZA was approved in Taiwan on August 28, 2019, for the treatment of acute influenza Types A and B in patients aged 12 years of age and older.16

Shionogi and the Roche Group, which includes Genentech in the U.S., have a license and collaboration agreement to further develop and commercialize XOFLUZA globally. Under the terms of this agreement, Roche Group holds worldwide rights to XOFLUZA excluding Japan and Taiwan, which will be retained exclusively by Shionogi & Co., Ltd. XOFLUZA is currently available across the U.S. for the treatment of acute, uncomplicated influenza in people 12 years of age or older.17 The U.S. Food and Drug Administration (FDA) has accepted a supplemental NDA for XOFLUZA for the treatment of influenza in individuals at high-risk for influenza-related complications 12 years and older. The PDUFA date for an FDA decision is November 4, 2019.18 For more information, please refer to the XOFLUZA website.

Roche is now conducting a Phase III development program including children under the age of one year, and severely ill, hospitalized patients, as well as to assess the potential to reduce transmission of influenza from an infected person to healthy people. Shionogi is assessing the potential of XOFLUZA as a post-exposure prophylaxis treatment to prevent the spread of influenza in adults and children, and positive results were obtained in the Phase III study.19

About Influenza

Seasonal and pandemic influenza remain a major public health concern, and novel influenza drugs that will offer significant improvement over current therapy are urgently needed. Globally, seasonal epidemics result in three-to-five million cases of severe disease, millions of hospitalizations and up to 650,000 deaths every year.20-24

About Shionogi

Shionogi & Co., Ltd. is a Japanese major research-driven pharmaceutical company dedicated to bringing benefits to patients based on its corporate philosophy of “supplying the best possible medicine to protect the health and wellbeing of the patients we serve.” The company currently markets products in several therapeutic areas including anti-infectives, pain, cardiovascular diseases, and gastroenterology. Our pipeline is focused on infectious disease, pain, CNS, and oncology. For more information on Shionogi & Co., Ltd., visit www.shionogi.co.jp/en. Shionogi Inc. is the U.S. subsidiary of Shionogi & Co., Ltd. based in N.J. For more information on Shionogi Inc., please visit https://www.shionogi.com/.

Forward-Looking Statements

This announcement contains forward-looking statements. These statements are based on expectations in light of the information currently available, assumptions that are subject to risks and uncertainties which could cause actual results to differ materially from these statements. Risks and uncertainties include general domestic and international economic conditions such as general industry and market conditions, and changes of interest rate and currency exchange rate. These risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, completion and discontinuation of clinical trials; obtaining regulatory approvals; claims and concerns about product safety and efficacy; technological advances; adverse outcome of important litigation; domestic and foreign healthcare reforms and changes of laws and regulations. Also for existing products, there are manufacturing and marketing risks, which include, but are not limited to, inability to build production capacity to meet demand, unavailability of raw materials, and entry of competitive products. The company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events, or otherwise.

References

  1. Ito A, Nishikawa T, Matsumoto S, et al. Siderophore Cephalosporin Cefiderocol Utilizes Ferric Iron Transporter Systems for Antibacterial Activity against Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2016;60(12):7396−7401.
  2. Ito-Horiyama T, Ishii Y, Ito A, et al. Stability of Novel Siderophore Cephalosporin S-649266 against Clinically Relevant Carbapenemases. Antimicrob Agents Chemother. 2016;60(7):4384−4386.
  3. Tillotson GS. Trojan Horse Antibiotics—A Novel Way to Circumvent Gram-Negative Bacterial Resistance? Infectious Diseases: Research and Treatment. 2016;9:45−52. doi:10.4137/IDRT.S31567
  4. Hackel M, Tsuji M, Yamano Y, et al. In Vitro Activity of the Siderophore Cephalosporin, Cefiderocol, Against a Recent Collection of Clinically Relevant Gram-Negative Bacilli from North America and Europe, Including Carbapenem Non-Susceptible Isolates: The SIDERO-WT-2014 Study. Antimicrob Agents Chemother. 2017;61(9):e00093−17. doi.org/10.1128/AAC.00093-17.
  5. Shionogi & Co, Ltd. Shionogi announces submission of cefiderocol marketing authorisation application. April 1, 2019. Retrieved from http://www.shionogi.co.jp/en/company/news/2019/pmrltj000000418y-att/e_190401_2.pdf.
  6. World Health Organization. Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics. February 27, 2017. Retrieved from https://www.who.int/medicines/publications/global-priority-list-antibiotic-resistant-bacteria/en/.
  7. Diene SM, Rolain JM. Carbapenemase genes and genetic platforms in gram-negative bacilli: Enterobacteriaceae, Pseudomonas and Acinetobacter species. Clin Microbiol Infect 2014; 20:831−38.
  8. Livermore DM. Current epidemiology and growing resistance of gram-negative pathogens. Korean J Intern Med 2012; 27:128−42.
  9. Brooke JS. Stenotrophomonas maltophilia: an emerging global opportunistic pathogen. Clin Microbiol Rev 2012; 25:2−41.
  10. Tangden T, Giske CG. Global dissemination of extensively drug-resistant carbapenemase-producing Enterobacteriaceae: clinical perspectives on detection, treatment and infection control. J Intern Med 2015; 277:501−12.
  11. Centers for Disease Control and Prevention (CDC). Antibiotic Resistance Threats in the United States 2013. Retrieved from https://www.cdc.gov/drugresistance/pdf/ar-threats-2013-508.pdf.
  12. European Centre for Disease Prevention and Control (ECDC). Technical Report: the bacterial challenge: time to react. 2009. Retrieved from

    https://ecdc.europa.eu/sites/portal/files/media/en/publications/Publications/0909_TER_The_Bacterial_Challenge_Time_to_React.pdf.
  13. Noshi et al. In Vitro Characterization of Baloxavir Acid, a First-in-Class Cap-Dependent Endonuclease Inhibitor of the Influenza Virus Polymerase PA Subunit. Antiviral Research 2018;160:109-117.
  14. Taniguchi K, Ando Y, Nobori H, Toba S, Noshi T, Kobayashi M, et al. Inhibition of avian-origin influenza A(H7N9) virus by the novel cap-dependent endonuclease inhibitor baloxavir marboxil. Sci Rep. 2019;9: 3466.
  15. Shionogi & Co, Ltd. XOFLUZATM (Baloxavir Marboxil) Tablets 10mg/20mg for the Treatment of Influenza Types A and B launched in Japan. March 14, 2018. Retrieved from http://www.shionogi.co.jp/en/company/news/2018/pmrltj0000003oid-att/e180314.pdf.
  16. Shionogi & Co, Ltd. Shionogi Announces XOFLUZA® Tablets 20mg for The Treatment of Influenza Types A and B in Patients 12 years of Age and older Approved in Taiwan. August 29, 2019. Retrieved from http://www.shionogi.co.jp/en/company/news/2019/pmrltj00000049g5-att/e_190829.pdf.
  17. Shionogi & Co, Ltd. Shionogi Announces FDA Approval of XOFLUZATM (Baloxavir Marboxil) – for the Treatment of Acute, Uncomplicated Influenza. October 25, 2018. Retrieved from http://www.shionogi.co.jp/en/company/news/2018/pmrltj0000003xss-att/e_181025.pdf.
  18. FDA Accepts XOFLUZATM (Baloxavir Marboxil) Supplemental New Drug Application for the Treatment of Influenza in Individuals at High Risk for Influenza-Related Complications. March 6, 2019. Retrieved from http://www.shionogi.co.jp/en/company/news/2019/pmrltj00000040ph-att/e_20190306.pdf.
  19. Shionogi & Co, Ltd. Shionogi Announces Positive Post-Exposure Prophylaxis Results for XOFLUZA® in Phase III Study (BLOCKSTONE) of Influenza Virus Infection in Household Members. September 2, 2019. Retrieved from http://www.shionogi.co.jp/en/company/news/2019/pmrltj00000049lh-att/190902_1_e.pdf.
  20. World Health Organization. Up to 650 000 people die of respiratory diseases linked to seasonal flu each year. December 14, 2017. Retrieved from http://www.who.int/mediacentre/news/releases/2017/seasonal-flu/en/.
  21. World Health Organization. Influenza (Seasonal). November 6, 2018. Retrieved from http://www.who.int/mediacentre/factsheets/fs211/en/.
  22. Baxter D. Evaluating the case for trivalent or quadrivalent influenza vaccines. Hum Vaccin Immunother. 2016; 12(10):2712-2717.
  23. Centers for Disease Control and Prevention (CDC). Estimated Influenza Illnesses, Medical Visits, Hospitalizations, and Deaths Averted by Vaccination. February 21, 2019. Retrieved from https://www.cdc.gov/flu/about/burden-averted/index.htm.
  24. Nair H, et al. Global burden of respiratory infections due to seasonal influenza in young children: a systematic review and meta-analysis. Lancet. 2011 Dec 3;378(9807):1917-30.

 

Contacts

For further information:
Shionogi & Co., Ltd.

Corporate Communications

Telephone: +81-6-6209-7885

Fax: +81-6-6229-9596

Shionogi Inc. U.S. Media

Lindsay Bohlander

Director, Advocacy & PR

+1 973-307-3718

lindsay.bohlander@shionogi.com

Exit mobile version